Drug Profile
Research programme: anti-HIV compounds - ViiV Healthcare
Latest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer ViiV Healthcare
- Class Antiretrovirals; Small molecules
- Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors; HIV replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 04 Oct 2021 Discontinued - Phase-I for HIV infections in USA (unspecified route) (NCT03984812)
- 27 Sep 2021 Phase-I clinical trials in HIV infections in USA (unspecified route) (NCT03984812)
- 28 Mar 2020 No recent reports of development identified for preclinical development in HIV-infections in USA